NCT04097301 · REGISTRY CONDITION SEARCH

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: TERMINATED
Registry last update: 2022-01-19

The purpose of this first-in-man Phase I-IIa study is to evaluate the safety and antitumor activity of autologous CD44v6 CAR T-cells in patients with acute myeloid leukemia (AML) and multiple myeloma (MM).

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Phase I: Maximum Tolerated Dose (MTD) and the Recommended Phase IIa Dose of MLM-CAR44.1 T-cells in AML and MM

→

outcome · POSTED

Phase I: Overall Safety of Treatment With MLM-CAR44.1 T-cells

→

outcome · POSTED

Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 3 Months Post-infusion

→

outcome · POSTED

Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 6 Months Post-infusion

→

outcome · POSTED

Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 12 Months Post-infusion

→

outcome · POSTED

Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 24 Months Post-infusion

→

outcome · POSTED

Phase IIa: Hematological Disease Response to MLM-CAR44.1 T-cells in AML.

→

outcome · POSTED

Phase IIa: Hematological Disease Response to MLM-CAR44.1 T-cells in MM

→

outcome · POSTED

Phase I: Hematologic Disease Response to MLM-CAR44.1 T-cells in AML

→

outcome · POSTED

Phase I: Hematologic Disease Response to MLM-CAR44.1 T-cells in MM

→

outcome · POSTED

Phase I: The Levels of Circulating MLM-CAR44.1 T-cells in Blood Samples

→

outcome · POSTED

Phase I: The Percentage of Patients for Whom Activation of Suicide Gene Was Needed

→

outcome · POSTED

Phase IIa: Hematologic Disease Response in AML

→

outcome · POSTED

Phase IIa: Hematologic Disease Response in MM

→

outcome · POSTED

Phase IIa: Overall Survival (OS)

→

outcome · POSTED

Exploratory Outcome of Phase IIa: Percentages of Patients With Minimal Residual Disease

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: Patients must meet all the following inclusion criteria to be eligible for the study. 1. Written informed consent before any study-related procedure. 2. Adults and children: 1. Adults 18 to 75 (65) years old with AML or MM. 2. Children 1 to 17 years old with AML, only in Phase IIa. 3. Confirmed diagnosis of AML or MM as follows: 1. AML: Primary or secondary AML (any subtype except acute promyelocytic leukemia) according to World Health Organization (WHO) classification. 2. MM with measurable disease as defined by the International Myeloma Working Group (IMWG). 4. Patients with relapse or refractory disease: 1. AML patients must be unlikely to benefit from cytotoxic chemotherapy as follows: * Leukemia refractory to at least 2 induction attempts. * Leukemia in relapse within 1 year following complete response (CR) after at least 2 induction attempts. * High-risk leukemia in adults according to 2017 European LeukemiaNet (ELN) in first relapse after a hypomethylating agent or a cycle containing cytarabine at a dose ≥ 1g/sqm a day (e.g. FLAG-IDA), except for FLT3-mutated AML. * High-risk leukemia in children as defined by the Italian Association of Pediatric Hematology and Oncology (AIEOP). 2. Patients with MM must have a relapse or refractory disease after at least 4 different prior treatments in 3 treatment lines, or 4 treatments in 2 treatment lines in case of early relapsing patients (relapse in less than 1.5 years). Treatments include: * Proteasome inhibitor * High-dose alkylating agent if patients less than 70 years old * Immunomodulatory drug (IMID) * A monoclonal antibody (i.e. anti CD38 monoclonal antibody) 5. Positive CD44v6 expression on tumor cells by flow cytometry. 6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. 7. Life expectancy of at least 12 weeks. 8. Adequate organ function (hepatic, cardiac, pulmonary). 9. Recovery from toxicities of clinical consequence attributed to previous chemotherapy to CTCAE v5.0 Grade 1 (i.e., certain toxicities such as alopecia will not be considered in this category). 10. Ability to comply with study procedures, including hospitalization and protocol-specified acquisition of blood and/or bone marrow specimens. 11. Willing to be followed up long term, i.e. a 15-year follow up as required by health authorities for cell and gene therapy products. 12. Women of childbearing potential must test negative for pregnancy at enrolment and during the study. Exclusion Criteria: At screening: patients must meet none of the following exclusion criteria to be eligible for the study: 1. History of or candidate for allogeneic stem cell transplantation. 2. Cardiovascular, pulmonary, renal, and hepatic functions that in the judgment of the investigator are insufficient for the patient to undergo investigational CAR T-cell therapy. 3. Any history of or suspected current autoimmune disorders (apart from vitiligo, resolved childhood atopic dermatitis, Graves' disease clinically controlled). 4. History of rheumatologic disorders requiring specific treatment at any time in the patient's medical history.
healthy Volunteers: false
maximum Age: 75 Years
minimum Age: 1 Year
sex: ALL
std Ages: CHILD
ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
PHASE I: i.v. single dose of MLM-CAR44.1 T-cells: 0.5 x 10E6/Kg or 1 x 10E6/Kg or 2 x10E6/Kg according to the BOIN design. PHASE IIa: i.v. single dose of MLM-CAR44.1 T-cells corresponding to the maximum tolerated dose (MTD). Phase I and IIa Pre-treatment: lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3
intervention Names
Drug: MLM-CAR44.1 T-cells at day 0 Single intravenous infusion
label
MLM-CAR44.1 T-cells infusion
type
EXPERIMENTAL

interventions

arm Group Labels
MLM-CAR44.1 T-cells infusion
description
Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.
name
MLM-CAR44.1 T-cells at day 0 Single intravenous infusion
other Names
CAR-T cells
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 8
type: ACTUAL

Registered outcome plans (not posted results)

other Outcomes

description
AML: proportion of patients with a molecular complete response (CR); MM: proportion of patients with a molecular CR.
measure
Exploratory Outcome of Phase IIa: Percentages of Patients With Minimal Residual Disease
time Frame
AML: 2 months after infusion, assessed as day 0. MM: 3 months after infusion, assessed as day 0

primary Outcomes

description
MTD established through BOIN design and the dose-limiting toxicities (DLTs) occurring following CAR T-cell infusion.
measure
Phase I: Maximum Tolerated Dose (MTD) and the Recommended Phase IIa Dose of MLM-CAR44.1 T-cells in AML and MM
time Frame
Within 30 days following CAR T-cell infusion, assessed as day 0
description
Safety will be evaluated by analyzing the type, frequency and severity of adverse events (AE) and by monitoring for systemic reactions (fever, tachycardia, nausea and vomiting, joint pain, skin rash). Overall, 3 study emergent serious adverse events (SAEs) were reported in patients treated with MLM-CAR44.1 T-cells.
measure
Phase I: Overall Safety of Treatment With MLM-CAR44.1 T-cells
time Frame
For 30 days following CAR T-cell infusion, assessed as day 0.
description
The absence of replication competent retrovirus (RCR) in blood specimens: 3 months post-infusion will be monitored by DNA PCR for the Galv gene. RCR search was conducted centrally using a quantitative molecular test, (real time quantitative PCR, q-PCR analysis) determining the absence of RCR by DNA PCR for the Galv and gag-pol genes on genomic DNA from patient's peripheral blood lymphocytes. The objective of this q-PCR analysis is to exclude the presence of RCR originated by recombination with PG13 packaging cell sequences by detecting the Galv and gag-pol transcripts in the transduced cells. The absence of the Galv and gag-pol transcripts can exclude the presence of an RCR, while its presence is not sufficient to indicate the presence of an RCR, and in this case further analysis is required.
measure
Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 3 Months Post-infusion
time Frame
3 months after infusion (assessed as day 0)
description
The absence of replication competent retrovirus (RCR) in blood specimens will be monitored by DNA PCR for the Galv gene. RCR search was conducted centrally using a quantitative molecular test, (real time quantitative PCR, q-PCR analysis) determining the absence of RCR by DNA PCR for the Galv and gag-pol genes on genomic DNA from patient's peripheral blood lymphocytes. The objective of this q-PCR analysis is to exclude the presence of RCR originated by recombination with PG13 packaging cell sequences by detecting the Galv and gag-pol transcripts in the transduced cells. The absence of the Galv and gag-pol transcripts can exclude the presence of an RCR, while its presence is not sufficient to indicate the presence of an RCR, and in this case further analysis is required
measure
Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 6 Months Post-infusion
time Frame
6 months after infusion (assessed as day 0)
description
The absence of replication competent retrovirus (RCR) in blood specimens will be monitored by DNA PCR for the Galv gene.
measure
Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 12 Months Post-infusion
time Frame
12 months after infusion (assessed as day 0)
description
The absence of replication competent retrovirus (RCR) in blood specimens will be monitored by DNA PCR for the Galv gene.
measure
Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 24 Months Post-infusion
time Frame
24 months after infusion (assessed as day 0)
description
The hematologic disease response will be classified according to ELN criteria.
measure
Phase IIa: Hematological Disease Response to MLM-CAR44.1 T-cells in AML.
time Frame
2 months after MLM-CAR44.1 T-cell infusion, assessed as day 0
description
The hematologic disease response will be classified according to IMWG criteria
measure
Phase IIa: Hematological Disease Response to MLM-CAR44.1 T-cells in MM
time Frame
3 months after T-cell infusion, assessed as day 0

secondary Outcomes

description
The hematologic disease response will be classified with the following response criteria: complete response (CR), incomplete response (CRi) and partial response (PR) according to ELN criteria.
measure
Phase I: Hematologic Disease Response to MLM-CAR44.1 T-cells in AML
time Frame
1 and 2 months following T-cell infusion, assessed as day 0
description
Hematologic disease response evaluated at Day 28 following CART-cell infusion, as overall response rate (ORR), stringent complete response (sCR), CR, very good partial response (VGPR) and partial response (PR).
measure
Phase I: Hematologic Disease Response to MLM-CAR44.1 T-cells in MM
time Frame
1 and 3 months following T-cell infusion, assessed as day 0
description
The levels will be evaluated by flow cytometry and qPCR (in vivo pharmacokinetic profile).
measure
Phase I: The Levels of Circulating MLM-CAR44.1 T-cells in Blood Samples
time Frame
At day 7, 14, 21, 28, 60, 90, 180 from infusion, assessed as day 0
description
Suicide gene activation and elimination of transduced cells will be established through administration of ganciclovir in case of cytokine-release syndrome (CRS) and other MLM-CAR44.1 T-cell related toxicities.
measure
Phase I: The Percentage of Patients for Whom Activation of Suicide Gene Was Needed
time Frame
At day 7, 14, 21, 28, 60, 90, 180 from infusion, assessed as day 0
description
The hematologic disease response will be classified with the following response criteria: complete response (CR), incomplete response (CRi) and partial response (PR) according to ELN criteria.
measure
Phase IIa: Hematologic Disease Response in AML
time Frame
1, 2 and 6 months after MLM-CAR44.1 T-cell infusion, assessed as day 0.
description
The hematologic disease response will be defined based on the overall response rate (ORR): stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to IMWG criteria
measure
Phase IIa: Hematologic Disease Response in MM
time Frame
1, 2 and 6 months after T-cell infusion, assessed as day 0
description
Overall Survival (OS) is defined as the time from the date of MLM-CAR44.1 T-cell infusion to the date of last follow-up or death due to any cause, whichever occurs first. One patients out of the 2 treated was still alive at the date of the early study termination. One patient died after EURE-CART-1 cell infusion, at day 121, for disease progression.
measure
Phase IIa: Overall Survival (OS)
time Frame
At the date of the early study termination

Full study description

brief Summary: The purpose of this first-in-man Phase I-IIa study is to evaluate the safety and antitumor activity of autologous CD44v6 CAR T-cells in patients with acute myeloid leukemia (AML) and multiple myeloma (MM).
detailed Description: The study is a seamless Phase I/IIa, open-label, multicenter clinical trial that combines Phase I dose escalation based on toxicity with Phase IIa dose expansion based on antitumor activity. Considering the "first in human" nature of this clinical study, the Bayesian Optimal Interval Design (BOIN) has been chosen to minimize any risks of exposure to the novel CD44v6 CAR T-cells during dose escalation. The study population is made up of patients with relapsed/refractory AML or MM expressing CD44v6. The medicinal product under investigation (MLM-CAR44.1 T-cells) is patient specific as it is prepared starting from lymphocytes of the patient collected through lymphocyte apheresis. These autologous T-cells are expanded in vitro in large numbers and genetically modified to express the CAR CD44v6ΔNL gene and thus acquire antitumor functions. As a safety feature, the MLM-CAR44.1 T-cells are genetically modified to also express the HSV-TK Mut2 gene (suicide gene), which can be selectively activated in case of severe toxicity through the administration of ganciclovir (GCV), leading to the death of proliferating CAR T-cells. The aim of this study is to assess the safety, antitumor activity and feasibility of CD44v6 CAR T cell immunotherapy in AML and MM.

Source references

references

citation
Stornaiuolo A, Valentinis B, Sirini C, Scavullo C, Asperti C, Zhou D, Martinez De La Torre Y, Corna S, Casucci M, Porcellini S, Traversari C. Characterization and Functional Analysis of CD44v6.CAR T Cells Endowed with a New Low-Affinity Nerve Growth Factor Receptor-Based Spacer. Hum Gene Ther. 2021 Jul;32(13-14):744-760. doi: 10.1089/hum.2020.216. Epub 2021 May 5.
pmid
33554732
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-b1a891fc41aa66a878ce
requested nct id
NCT04097301
primary nct id
NCT04097301
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
1c8c58400e15c9b5eb0d773b06002aa7363ec7b27ac86c9486cbaa6646a410ab
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-b1a891fc41aa66a878ce
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT04097301
occurrences
context exact
NCT04097301
end
11
exact text
NCT04097301
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/358/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
a844e12cb70f42a08f3494db7a19c4a8a6b6e21d146706d736aafc4c3fd941e5
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice